Q-omics provides the consensus-scored RBMY2QP profile across patient tissues and cancer cell-line models. RBMY2QP expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in COAD. Additionally, RBMY2QP RNA expression shows 4,152 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, and STAD as cancer lineages where RBMY2QP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.